SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (249)11/7/2001 9:25:20 PM
From: aknahow  Read Replies (1) | Respond to of 1022
 
Xoma will be taking such a fusion protein into clinic by early nest year. Gelonin uses a toxin related to but not ricin. Very early stage and have no idea if it will work.

BTW CEO says it is talking to 14 companies that will need to license its' cell expression technology. They are expected to do so soon. CEO stated yesterday that all phage companies are in violation of Xoma patents if they continue without getting a license.



To: Gary Mohilner who wrote (249)11/8/2001 12:26:39 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1022
 
>> While it's not a part of that article, it should be recognized that the majority of the MAB's that MEDX and others can create by themselves may have little or no curative benefits. <<

Why do you say that? A number of toxin conjugates have failed in the clinic (including two ricin conjugates from IMGN), while anti-CD20, anti-Her2/neu, anti-RSV, etc. have proven to be quite effective.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News